Bladder cancer

L Dyrskjøt, DE Hansel, JA Efstathiou… - Nature Reviews …, 2023 - nature.com
Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Bladder cancer: a review

AT Lenis, PM Lec, K Chamie - Jama, 2020 - jamanetwork.com
Importance Bladder cancer is a common malignancy in women and is the fourth most
common malignancy in men. Bladder cancer ranges from unaggressive and usually …

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

SA Boorjian, M Alemozaffar, BR Konety… - The Lancet …, 2021 - thelancet.com
Background BCG is the most effective therapy for high-risk non-muscle-invasive bladder
cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient …

Bladder cancer: diagnosis and treatment

KC DeGEORGE, HR Holt, SC Hodges - American family physician, 2017 - aafp.org
Bladder cancer is the sixth most prevalent malignancy in the United States and causes more
than 16,000 deaths annually. The most common clinical presentation is asymptomatic …

Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial

JE Gschwend, MM Heck, J Lehmann, H Rübben… - European urology, 2019 - Elsevier
Background The extent of lymph node dissection (LND) in bladder cancer (BCa) patients at
the time of radical cystectomy may affect oncologic outcome. Objective To evaluate whether …

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

J Bellmunt, M Hussain, JE Gschwend, P Albers… - The Lancet …, 2021 - thelancet.com
Background Despite standard curative-intent treatment with neoadjuvant cisplatin-based
chemotherapy, followed by radical surgery in eligible patients, muscle-invasive urothelial …

Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology

PE Spiess, N Agarwal, R Bangs, SA Boorjian… - Journal of the National …, 2017 - jnccn.org
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder …

Phase 2 trial of atezolizumab in bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer: SWOG S1605

PC Black, CM Tangen, P Singh, DJ McConkey… - European urology, 2023 - Elsevier
Background Although radical cystectomy (RC) is the standard of care for patients with
bacillus Calmette-Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder …

[HTML][HTML] Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer

J Liu, TY Yang, LQ Dai, K Shi, Y Hao, BY Chu, DR Hu… - Bioactive Materials, 2024 - Elsevier
Surgical resection remains the prefer option for bladder cancer treatment. However, the
effectiveness of surgery is usually limited for the high recurrence rate and poor prognosis …

Characteristics and clinical significance of histological variants of bladder cancer

M Moschini, D D'andrea, S Korn, Y Irmak… - Nature Reviews …, 2017 - nature.com
In the past 10 years evidence for the clinical relevance of variant histology in urinary bladder
cancer has been increasing. This increase has resulted in new classifications of urothelial …